Cardiac involvement, present in about 50% of patients, is the leading cause of morbidity and mortality in immunoglobulin light chain (AL) amyloidosis. Cardiac biomarkers can risk stratify the patients, and those with advanced (stage III) 1 disease, who have the poorest prognosis, regardless of treatment, with a median survival of 3.5-7 months.
chain (FLC) levels in the interval between planned OHT and HDM/SCT, to help guide the need for treatment.
Seventeen patients were treated following collaborative protocols at the Boston Medical Center Amyloidosis Center and the Massachusetts General Hospital Heart Failure Program, between 1997 and 2013. Data were reviewed with approval of both hospitals' Institutional Review Boards. All patients had a diagnosis of AL amyloidosis; patients with symptomatic multiple myeloma (BM plasma cell percentage 430% or hypercalcemia, anemia or lytic bone disease) were not considered OHT candidates.
Of the 17 patients who underwent planned OHT followed by HDM/SCT, 12 had FLC levels available pre-and post-OHT for assessment of progression of disease before HDM/SCT (Table 1) . Their median age was 57 years (range 42-60), and 8 of the patients were male. Seven of the 12 patients received chemotherapy before OHT, consisting of melphalan and dexamethasone for 3 patients, bortezomib (single agent) for 1 patient, bortezomib and dexamethasone for 1 patient, CY with bortezomib and dexamethasone for 1 patient, and dexamethasone single agent for 1 patient, at the treating physician's discretion. Following OHT, no further antiplasma cell treatment was administered. The patients were treated with a calcineurin inhibitor (CNI), prednisone, and mycophenolate mofetil (MMF) for immunosuppression; 1 patient received azathioprine instead of MMF owing to intolerance. Once patients were on a low-prednisone dose and without sign of organ rejection, and fully recovered from OHT, they underwent The ΔFLC, defined as the difference between involved and uninvolved FLC level, was used to assess the changes in the underlying plasma cell disease during the period between OHT and HDM/SCT (Figure 1) . In four patients, the ΔFLC declined more than 50% during this period, consistent with a PR, two patients had a minor response (ΔFLC reduction of 25-50%) and five patients had a stable ΔFLC; only one patient had progression of disease, with an increase in ΔFLC of 450%. Responses were seen in four of seven patients who received the antiplasma cell treatment before OHT and two of five who did not; it is not clear if the pre-OHT treatment contributed to the the ΔFLC changes in subsequent months.
Two patients (17%) died within 100 days of HDM/SCT, one from complications of multiorgan dysfunction from amyloidosis and the other from septic shock. At 12 months post HDM/SCT, survival was 58% (one patient not evaluable), and all evaluable patients obtained at least a hematologic PR. No statistically significant difference in survival was detected on the basis of plasma cell burden at diagnosis or on administration, or not of treatment pre-OHT.
In conclusion, in this series of 12 patients, only 1 patient had evidence of hematologic progression of disease during the 5-to 10-month period between OHT and HDM/SCT, suggesting that the combination of CNI, corticosteroid and MMF may control the underlying plasma cell dyscrasia during this time. This hypothesis can be explored in future clinical trials, as can the potential role of alternative antiplasma cell therapies rather than HDM/SCT.
Pre-OHT
Pre-SCT ΔFLC (mg/L) Figure 1 . Trends in serum FLC levels expressed as ΔFLC (mg/L) from time before OHT to time before high-dose melphalan chemotherapy and pre-auto-SCT. Each line represents an individual patient.
